Ruben Osnabrugge

Ruben Osnabrugge, MD PhD, joined 415C in October 2023 where he serves as Partner. Prior to joining 415C, Ruben was an investment manager at EQT Lifesciences (formerly LSP), where he focused on medical devices, digital health and diagnostics. Prior, Ruben led the Value-Based Care strategy for Philips, where he was part of the global Chief Medical Office. He also supported strategic deep dives and due diligence for Philips’s investments. Moreover, he represented Philips at Medtech Europe and led a World Economic Forum project with Intermountain Healthcare and Novartis.

Before, Ruben underwent surgical training in cardio-thoracic surgery with a special interest in interventional cardiology at Erasmus University Medical Center, Rotterdam. As part of this training, he also performed general and vascular surgery and worked at the intensive care. Ruben is a recognized expert in cost-effectiveness and health outcomes research, especially in coronary revascularization and structural heart interventions. He received a Fulbright Scholarship which he spent at the Mid-America Heart Institute in Kansas City to work on pivotal cardiovascular clinical trials. He has (co-)authored >40 articles in top peer-reviewed medical journals including JAMA, European Heart Journal, and the Journal of the American College of Cardiology, two chapters in the ESC Textbook of Cardiovascular Medicine and a European clinical guideline. Moreover, he was editorial board member at Eurointervention Journal and faculty at leading interventional cardiology and surgical societies EuroPCR and EACTS, from which he also received a young investigator award.

Ruben holds MD and PhD degrees from Erasmus Medical School in Rotterdam, a MSc in Clinical Research from NIHES and the Harvard School of Public Health, and a BSc in Health Economics from Erasmus School of Economics. Ruben lives in Munich, in his spare time he is an avid cyclist and enjoys family, traveling, good food and photography.